Literature DB >> 26649472

Early growth and development impairments in patients with ganglioside GM3 synthase deficiency.

H Wang1,2,3,4, A Wang1, D Wang1, A Bright1, V Sency1, A Zhou5, B Xin1.   

Abstract

Ganglioside GM3 synthase is a key enzyme involved in the biosynthesis of gangliosides. GM3 synthase deficiency (GSD) causes a complete absence of GM3 and all downstream biosynthetic derivatives. The individuals affected by this disorder manifest severe irritability, intractable seizures and profound intellectual disability. However, we have found that most newborns seem symptom-free for a period of time after birth. In order to further understand the onset of the disease, we investigated the early growth and development of patients with this condition through this study. We compared 37 affected individuals with their normal siblings and revealed that all children with GSD had relatively normal intrauterine growth and development, as their weight, length and head circumference were similar to their normal siblings at birth. However, the disease progresses quickly after birth and causes significant constitutional impairments of growth and development by 6 months of age. Neither breastfeeding nor gastrostomy tube placement made significant difference on growth and development as all groups of patients showed the similar pattern. We conclude that GSD causes significant postnatal growth and developmental impairments and the amount of gangliosides in breast milk and general nutritional intervention do not seem to alter these outcomes.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ST3GAL5; ganglioside GM3 synthase deficiency; mutation; phenotype

Mesh:

Substances:

Year:  2016        PMID: 26649472     DOI: 10.1111/cge.12703

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

1.  ST3GAL5-Related Disorders: A Deficiency in Ganglioside Metabolism and a Genetic Cause of Intellectual Disability and Choreoathetosis.

Authors:  Eliza Gordon-Lipkin; Julie S Cohen; Siddharth Srivastava; Bruno P Soares; Eric Levey; Ali Fatemi
Journal:  J Child Neurol       Date:  2018-09-05       Impact factor: 1.987

2.  Dystonia Due to GM3 Synthase Deficiency.

Authors:  Alexander S Wang; Camilla Kilbane
Journal:  Mov Disord Clin Pract       Date:  2022-01-05

3.  Mass spectrometric quantification of plasma glycosphingolipids in human GM3 ganglioside deficiency.

Authors:  Kazuhiro Aoki; Adam D Heaps; Kevin A Strauss; Michael Tiemeyer
Journal:  Clin Mass Spectrom       Date:  2019-03-16

4.  Oral Ganglioside Supplement Improves Growth and Development in Patients with Ganglioside GM3 Synthase Deficiency.

Authors:  Heng Wang; Valerie Sency; Paul McJarrow; Alicia Bright; Qianyang Huang; Karen Cechner; Julia Szekely; JoAnn Brace; Andi Wang; Danting Liu; Angela Rowan; Max Wiznitzer; Aimin Zhou; Baozhong Xin
Journal:  JIMD Rep       Date:  2018-09-13

5.  The Metabolic Signatures of Surviving Cotwins in Cases of Single Intrauterine Fetal Death During Monochorionic Diamniotic Pregnancy: A Prospective Case-Control Study.

Authors:  Xiyao Liu; Huijia Fu; Li Wen; Fangyu Zhu; Yue Wu; Zhi Chen; Richard Saffery; Chang Chen; Hongbo Qi; Chao Tong; Philip N Baker; Mark D Kilby
Journal:  Front Mol Biosci       Date:  2022-04-08

6.  A novel frameshift pathogenic variant in ST3GAL5 causing salt and pepper developmental regression syndrome (SPDRS): A case report.

Authors:  Jamal Manoochehri; Seyed Alireza Dastgheib; Hossein Jafari Khamirani; Maryam Mollaie; Zahra Sharifi; Sina Zoghi; Seyed Mohammad Bagher Tabei; Sanaz Mohammadi; Fatemeh Dehghanian; Zahra Farbod; Mehdi Dianatpour
Journal:  Hum Genome Var       Date:  2021-08-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.